Evidence map›Paper›PMID 33860922›Full record

ArticleCNS drugs2021

Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.

Emma Morton, Venkat Bhat, Peter Giacobbe, Wendy Lou, Erin E Michalak, Shane McInerney, Trisha Chakrabarty, Benicio N Frey, Roumen V Milev, Daniel J Müller and 5 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in CNS drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05017311 (Optimized Predictive Treatment In Medications for Unipolar Major Depression), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05017311 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

TypeinterventionalSponsorNova Scotia Health AuthorityRan2023 to 2029Enrolled400ConditionsMajor Depressive DisorderArmsEscitalopram, Brexpiprazole
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Psychophysical and Social Functioning of Patients with Chronic Obstructive Lung Disease and Depression.European journal of investigation in health, psychology and education · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Emma MortonDepartment of Psychiatry, University of British Columbia, 5950 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada. emma.morton@ubc.ca.ORCID 0000-0001-6179-1983
Venkat BhatDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Peter GiacobbeDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Wendy LouDalla Lane School of Public Health, University of Toronto, Toronto, ON, Canada.
Erin E MichalakDepartment of Psychiatry, University of British Columbia, 5950 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada.
Shane McInerneyDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Trisha ChakrabartyDepartment of Psychiatry, University of British Columbia, 5950 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada.
Benicio N FreyDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
Roumen V MilevDepartments of Psychiatry and Psychology, Queen's University, Kingston, ON, Canada.
Daniel J MüllerDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Sagar V ParikhDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
Susan RotzingerDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Sidney H KennedyDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Raymond W LamDepartment of Psychiatry, University of British Columbia, 5950 Wesbrook Mall, Vancouver, BC, V6T 2A1, Canada.
CAN-BIND Investigator Team
University of Toronto · CAUniversity of British Columbia · CAMcMaster University · CAQueen's University · CAUniversity of British Columbia Hospital · CAUniversity of Michigan · US

Funding

CIHR
6 · The paper itself

Abstract

backgroundNon-response to first-line treatment for major depressive disorder (MDD) is common; for such individuals, quality of life (QoL) impairments can be severe. Identifying predictors of QoL changes may support the management of cases with persistent depressive symptoms despite adequate initial pharmacological/psychological treatment.

objectiveThe present study aimed to explore predictors of domain-specific QoL improvement following adjunctive aripiprazole treatment for inadequate response to initial antidepressant therapy.

methodsWe evaluated secondary QoL outcomes from a CAN-BIND (Canadian Biomarker Integration Network in Depression) study in patients with MDD who did not respond to an initial 8 weeks of escitalopram and received a further 8 weeks of adjunctive aripiprazole (n = 96). Physical, psychological, social, and environmental QoL domains were assessed using the World Health Organization QoL Scale Brief Version (WHOQOL-BREF). Clinician-rated depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Functioning was measured with the Sheehan Disability Scale (SDS). Satisfaction with medication was assessed with a single item from the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Exploratory t-tests were used to describe domain score changes. A hierarchical linear regression was used to explore demographic, clinical, and treatment-related predictors of improvement.

resultsAcross domains, QoL improved with adjunctive aripiprazole treatment. Satisfaction with medication and MADRS and SDS scores similarly improved. Symptom reduction was a predictor for positive change to physical and psychological QoL; functioning improvements were predictive of increases to all QoL domains. Satisfaction with medication predicted improvements to physical and psychological domains, whereas number of medication trials was a predictor of worsening QoL in the physical domain.

conclusionThe final model explained the most variance in psychological (68%) and physical (67%) QoL. Less variance was explained for environmental (43%) and social QoL (33%), highlighting a need for further exploration of predictors in these domains. Strategies such as functional remediation may have potential to support QoL for individuals with persistent depressive symptoms. CLINICAL TRIALS REGISTRY: ClinicalTrials.gov identifier: NCT016557.

Indexed as

AripiprazoleEscitalopramMajor Depressive DisorderActivities of Daily LivingAdultAntidepressive AgentsCanadaDrug MonitoringDrug Therapy, CombinationFemaleHumansMalePhysical Functional PerformancePsychiatric Status Rating ScalesQuality of LifeSocial InteractionAntidepressive AgentsAripiprazoleEscitalopram

Identifiers

PMID33860922
OpenAlexW3156691689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.